Replies to post #24544 on RespireRx Pharmaceuticals Inc (fka RSPI)

[jerrydylan]

Merck paid $1 billion for an RNAI business...which given all the hoopla over FDA stringentcy, how are they going to get one of these drugs to market...? One thing is for sure about RD-it's pretty damn obvious- and all the Ampakines have been tested in animals by now-the entire pre-clinical pipeline. And there is a need, how large is debatable. It's possible availability can open markets and off label use ( I know off-label use is risky) Considering we have a $15 million cap, it would seem to me someone might actually want to poach Cortex, whole shot $50 million. $1 pershare